Immune complexes consisting of heparin, platelet factor 4 (PF4) and PF4/heparin- 
Introduction
HIT is the most common drug-induced, immune-mediated thrombocytopenia and usually occurs after 3-6 days of heparin treatment 1, 2 . Antibodies that recognize PF4 and heparin to form immune complexes are central to the pathogenesis of HIT 2 . PF4/heparin-specific antibodies in HIT patients are predominantly polyclonal immunoglobulin G1 (IgG1)
isotype with some IgG2 2-4 . IgG/PF4/heparin immune complexes bind FcγRIIA on the platelet surface and induce platelet activation, resulting in thrombocytopenia and a high risk of serious arterial and/or venous thrombosis and thromboembolism 5, 6 .
Glycosaminoglycans (GAG) other than heparin are widely expressed on endothelial cells and elsewhere in the body and react with PF4 to produce structural changes recognized by HIT antibodies 7 . Other non-GAG polyanionic macromolecules such as DNA and RNA similarly modify PF4 8 . Thus, humans are exposed to structurally modified, immunogenic PF4 throughout their lives and B-cell tolerance to epitopes recognized by HIT antibodies is likely established early in life, possibly explaining why only 3% of patients given heparin experience HIT 9 . B cell tolerance to self-antigens is mediated by clonal deletion and receptor editing, leading to elimination of PF4/heparinspecific B cells, and by anergy, in which B cells are reversibly inactivated
10
.
Study design Mice
PKCδ-deficient mice were derived from Anning Lin, University of Chicago with permission from Dr. Keiichi Nakayama at Kyushu University, Japan 11 , and maintained on a C57BL/6 genetic background. Experimental and control mice were 8-10 weeks old. 
Activation of B cells and detection of PF4/heparin-specific antibodies
In vitro activation of human or mouse B cells, in vivo activation of mouse B cells by CpG challenge, and measurement of human PF4 (hPF4)/heparin-or mouse PF4 (mPF4)/heparin-specific antibodies by ELISA were performed as previously described [12] [13] [14] [15] [16] . G Arepally, Duke University kindly provided mPF4. Human studies were approved by the Institutional Review Board of Blood Center of Wisconsin. This study was conducted in accordance with the Declaration of Helsinki.
Estimation of PF4/heparin-specific B cell frequencies in PBMCs
The frequency of B cells in cultured human PBMCs that produce PF4/heparin-specific antibodies was estimated by most-probable-number (MPN) analysis (Table S1 ).
Statistical analysis
Statistical analysis was performed with the Mann-Whitney test for unpaired data and the Wilcoxon signed-rank test for paired data. The pre-determined alpha level of significance is 0.05. (Table S1 ). Therefore, PBMCs from healthy human adults in this study contain relatively large numbers of tolerant hPF4/heparin-specific B cells that can be activated to produce IgM antibodies upon in vitro polyclonal stimulation.
We examined whether PF4/heparin-specific B cells like those found in humans can be demonstrated in healthy wild-type mice. Splenic B cells were purified from non- We also examined whether the pre-existing, tolerant PF4/heparin-specific B cells in wild-type mice can produce antibodies following polyclonal stimulation in vivo. Wildtype mice had basal levels of PF4/heparin-specific IgM antibodies and markedly increased production of these IgMs following CpG injection ( Figure 2A ). Some wild-type mice produced PF4/heparin-specific IgG antibodies following CpG challenge ( Figure   2A ). These IgMs and IgGs reacted specifically with mPF4/heparin complexes but less well with mPF4 alone and their reactions were inhibited by excess heparin (Figure 2A 
org From
Thus, pre-existing, inactive PF4/heparin-specific B cells in wild-type mice can be activated by polyclonal stimulation to produce IgMs and even switch to IgGs in vivo.
Activation of pre-existing, inactive PF4/heparin-specific B cells to produce antibodies by polyclonal stimulation suggests B cell tolerance breakdown. To obtain further evidence that HIT antibody production is normally restricted by B cell tolerance, we examined the effect of protein kinase Cδ (PKCδ) deficiency on PF4/heparin-specific antibody production. Signaling molecule PKCδ controls B cell anergy and its deficiency impairs B cell tolerance, leading to autoantibody production in humans and mice 11, 19, 20 .
Non-manipulated PKCδ-deficient mice spontaneously produced significantly higher levels of PF4/heparin-specific IgMs than wild-type controls ( Figure 2B ). A significantly higher number of non-manipulated PKCδ-deficient mice also spontaneously produced elevated levels of PF4/heparin-specific IgGs relative to wild-type controls ( Figure 2C ).
These IgMs and IgGs specifically reacted with mPF4/heparin complexes but not mPF4 alone and their binding was inhibited by excess heparin (Figure 2D -E). These findings provide additional evidence that B cell tolerance controls PF4/heparin-specific B cells and that tolerance breakdown leads to spontaneous production of PF4/heparin-specific HIT antibodies.
PF4/heparin-specific B cell tolerance can be broke down by an inflammatory stimulus. By analogy, the inflammatory milieu associated with tissue trauma may account for the increased incidence of HIT antibodies and clinical HIT in patients given heparin during cardiopulmonary bypass or orthopedic surgery 21, 22 . The tolerance breakdown concept is consistent with the previously observed atypical immune response features of HIT patients, such as rapid generation and loss of anti-PF4/heparin antibodies and the 
